83 related articles for article (PubMed ID: 36472728)
1. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
2. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Aggarwal R; Heller G; Hillman DW; Xiao H; Picus J; Taplin ME; Dorff T; Appleman L; Weckstein D; Patnaik A; Bryce A; Shevrin D; Mohler J; Anderson D; Rao A; Tagawa S; Tan A; Halabi S; Dooley K; O'Brien P; Chen R; Ryan CJ; Eggener SE; Morris MJ;
J Clin Oncol; 2024 Apr; 42(10):1114-1123. PubMed ID: 38261983
[TBL] [Abstract][Full Text] [Related]
3. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
[TBL] [Abstract][Full Text] [Related]
4. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer.
Saad F; Shore ND
Ther Adv Med Oncol; 2021; 13():1758835921998586. PubMed ID: 34408793
[TBL] [Abstract][Full Text] [Related]
5. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18Â months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
Ulys A; Jankevicus F; Jievaltas M; Venckus R; Auskalnis S; Kardelis Z; Barisiene M; MacLean CM; van Os S; Larsen F
Prostate; 2024 May; 84(6):584-598. PubMed ID: 38311868
[TBL] [Abstract][Full Text] [Related]
8. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Nikitas J; Rettig M; Shen J; Reiter R; Lee A; Steinberg ML; Valle LF; Sachdeva A; Romero T; Calais J; Czernin J; Nickols NG; Kishan AU
Eur Urol; 2024 Mar; ():. PubMed ID: 38494380
[TBL] [Abstract][Full Text] [Related]
9. Impact of neoadjuvant relugolix on patient-reported sexual function and bother.
Hsueh JY; Gallagher L; Koh MJ; Eden S; Shah S; Wells M; Danner M; Zwart A; Ayoob M; Kumar D; Leger P; Dawson NA; Suy S; Rubin R; Collins SP
Front Oncol; 2024; 14():1377103. PubMed ID: 38665954
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
Szmulewitz R; Mohile S; Posadas E; Kunnavakkam R; Karrison T; Manchen E; Stadler WM
Eur Urol; 2009 Jul; 56(1):97-103. PubMed ID: 19282098
[TBL] [Abstract][Full Text] [Related]
11. A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia.
Marx G; Chowdhury S; Krieger L; Hovey E; Shapiro J; Tran B; Tan TH; Ng S; Woo HH
Asia Pac J Clin Oncol; 2024 Apr; ():. PubMed ID: 38639402
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
Morris MJ; Huang D; Kelly WK; Slovin SF; Stephenson RD; Eicher C; Delacruz A; Curley T; Schwartz LH; Scher HI
Eur Urol; 2009 Aug; 56(2):237-44. PubMed ID: 19375217
[TBL] [Abstract][Full Text] [Related]
13. Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
Kamada S; Sakamoto S; Kinoshita R; Zhao X; Kamasako T; Yamase R; Junryo R; Saito S; Sangjon P; Takei A; Yamada Y; Goto Y; Imamura Y; Iguchi T; Mizokami A; Suzuki H; Akakura K; Ichikawa T
Prostate; 2024 May; 84(7):636-643. PubMed ID: 38413843
[TBL] [Abstract][Full Text] [Related]
14. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series.
Dason S; Allard CB; Tong J; Shayegan B
Can Urol Assoc J; 2013; 7(5-6):E263-7. PubMed ID: 23766827
[TBL] [Abstract][Full Text] [Related]
15. Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer.
Yang Z; Shao Y; Huang H; Liu Y; Wang Z; Wang Y
World J Urol; 2024 Mar; 42(1):171. PubMed ID: 38506974
[TBL] [Abstract][Full Text] [Related]
16. Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial.
Ng CF; Yee CH; Chiu PK; Wong K; Lam D; Yuen VW; Lai PT; Teoh JY
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38653621
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.
Pieczonka CM; Twardowski P; Renzulli J; Hafron J; Boldt-Houle DM; Atkinson S; Eggener S
Rev Urol; 2018; 20(2):63-68. PubMed ID: 30288142
[TBL] [Abstract][Full Text] [Related]
18. Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies.
Klotz L; Tat T
BJUI Compass; 2024 Mar; 5(3):392-402. PubMed ID: 38481666
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer.
Myint ZW; St Clair WH; Strup SE; Yan D; Li N; Allison DB; McLouth LE; Ellis CS; Wang P; James AC; Hensley PJ; Otto DE; Arnold SM; DiPaola RS; Kolesar JM
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173971
[TBL] [Abstract][Full Text] [Related]
20. Apalutamide-associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy.
Tohi Y; Kataoka K; Miyai Y; Kaku Y; Dainichi T; Haba R; Tsunemori H; Sugimoto M
IJU Case Rep; 2021 Sep; 4(5):299-302. PubMed ID: 34497989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
